Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing registry study of infliximab (Leiting) in Chinese pediatric Crohn's disease
CTR20231580Phase 4Active
- Sponsor
- Mabpharm Limited
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in Crohn's disease, sponsored by Mabpharm Limited. Started Sep 2023; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20231580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231580.